Начало・Списък с акции・Cogent Biosciences Inc

Cogent Biosciences Inc

Затворен

33.29 -1.92

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

33.17

Максимум

33.46

Ключови измерители
By Trading Economics
Приходи	947K -96M
EPS	-0.52
Служители	258
EBITDA	537K -94M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+62.06% upside

Дивиденти
By Acuity
Следващи печалби	2.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-608M 6B
Предишно отваряне	35.21
Предишно затваряне	33.29

Cogent Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.09.2026 г., 23:51 ч. UTC

China's House Price Index YoY release on September 15 expected to show continued decline amid cautious market sentiment and rising global oil prices.

12.09.2026 г., 23:41 ч. UTC

Philadelphia Fed Manufacturing Index Set for Release Amid Heightened Market Sensitivity to Inflation and Interest Rate Hike Expectations.

12.09.2026 г., 23:41 ч. UTC

U.S. Building Permits Expected to Reach 1.41 Million for August Amid Mixed Housing Sentiment Ahead of September Release

12.09.2026 г., 23:41 ч. UTC

Housing Starts Data Release on September 17, 2026, Expected to Show Continued Caution Amid High Mortgage Rates and Recent Declines.

12.09.2026 г., 23:41 ч. UTC

Upcoming U.S. Building Permits Report on September 17, 2026, Expected to Reflect Economic Health Amid Stable Market Sentiment.

12.09.2026 г., 23:41 ч. UTC

Upcoming Housing Starts Data Release Amid Rising Mortgage Rates Raises Concerns for U.S. Construction Market

12.09.2026 г., 23:21 ч. UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in August Amid Mixed Economic Sentiment and Inflation Concerns

12.09.2026 г., 23:21 ч. UTC

U.S. Import Prices Expected to Rise 0.2% Amid Inflation Concerns and Fed Rate Speculation Following Geopolitical Tensions

12.09.2026 г., 23:21 ч. UTC

U.S. Export Prices Expected to Rise in August Amid Positive Economic Sentiment and Fed Rate Speculations

12.09.2026 г., 23:21 ч. UTC

U.S. Retail Sales Expected to Rise 0.9% in August Amid Cautious Market Sentiment Following July's Decline

12.09.2026 г., 23:11 ч. UTC

Canada's housing starts data release on September 16, 2026, expected at 235,000 units amid cautious market sentiment following July’s shortfall.

12.09.2026 г., 23:01 ч. UTC

NY Empire State Manufacturing Index Set for Release Amid Mixed Economic Sentiment and Inflation Concerns on September 15, 2026.

12.09.2026 г., 23:01 ч. UTC

Market Awaits ECB President Lagarde's Speech Amid Speculation of Future Rate Hikes and Leadership Changes Following Recent Interest Rate Increase.

12.09.2026 г., 22:51 ч. UTC

Brazil's Central Bank Set to Announce SELIC Rate Decision Amid Global Monetary Tightening and Rising Inflation Concerns on September 14, 2026.

12.09.2026 г., 22:51 ч. UTC

Japan's Core Inflation Rate Expected to Rise to 1.8% Amid Global Economic Pressures Ahead of Bank of Japan Meeting

12.09.2026 г., 22:51 ч. UTC

Japan's Upcoming Inflation Rate Report Expected to Reflect Mixed Signals Amid Rising Energy Costs and Producer Price Fluctuations

12.09.2026 г., 22:41 ч. UTC

Canada's August Inflation Rate Release on September 14 Expected to Show Continued Pressure Amid Geopolitical Tensions and Rising Oil Prices.

12.09.2026 г., 22:41 ч. UTC

Canada's Core Inflation Rate Expected to Rise to 2.4% Amid U.S. Economic Indicators and Speculation of Fed Interest Rate Hikes

12.09.2026 г., 22:41 ч. UTC

Rising U.S. 30-Year Mortgage Rates Exceed 7%, Threatening Housing Demand and Economic Growth Ahead of Key Central Bank Meetings

12.09.2026 г., 22:41 ч. UTC

Canada's Inflation Rate Expected to Hold Steady at 0.0% Amid Global Economic Concerns Ahead of September Release

12.09.2026 г., 22:41 ч. UTC

Macro News

The DAX 30 Index is lower in after-market trading, pressured by rising crude oil prices and concerns over Treasury yields and interest rate hikes.

12.09.2026 г., 22:31 ч. UTC

Japan's trade deficit forecasted at -1052.6 billion yen for August 2026 amid rising import costs and negative market sentiment.

12.09.2026 г., 22:31 ч. UTC

Japan's August Exports YoY Data Set for Release Amidst Cautious Market Sentiment and Economic Concerns

12.09.2026 г., 22:31 ч. UTC

Japan's Machinery Orders Expected to Decline Amid Market Volatility and Inflation Concerns

12.09.2026 г., 22:31 ч. UTC

Brazil's Retail Sales Report on September 15 Expected to Show Month-on-Month Growth Amid Inflationary Pressures

12.09.2026 г., 22:11 ч. UTC

Bank of England Expected to Maintain Interest Rate at 0.667% Amid Global Economic Caution and Inflation Concerns

12.09.2026 г., 21:01 ч. UTC

Oil (Brent) is trading lower during after-market hours, continuing a decline since Friday's close. The market shows weakness despite remaining above its 20-day moving average.

12.09.2026 г., 21:01 ч. UTC

India's August Inflation Rate Release on September 14 Expected at 4.8%, Amid Rising Global Energy Costs and Geopolitical Tensions

12.09.2026 г., 21:01 ч. UTC

EUR/PLN traded roughly flat during after-market hours, remaining around the middle of its one-month range with no specific news identified.

12.09.2026 г., 20:51 ч. UTC

API Crude Oil Stock Change Data Release on September 15 Expected to Show Continued Inventory Decline Amid Easing Geopolitical Tensions and Inflation Concerns.

Сравнение с други в отрасъла

Ценова промяна

Cogent Biosciences Inc Прогноза

Ценова цел

By TipRanks

62.06% нагоре

12-месечна прогноза

Среден 54.143 USD 62.06%

Висок 62 USD

Нисък 45 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Cogent Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Cogent Biosciences Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.